GINA LEMAN: Open Payments
NPI 1942569371 · BROWNSBURG, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$782 in 42 payments from 19 companies in 2025. Trend: 2023 $910 · 2024 $1,049 · 2025 $782
Food & beverage: $782
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 13 | $217 |
| PFIZER INC. | 5 | $111 |
| GlaxoSmithKline, LLC. | 3 | $77 |
| ABBVIE INC. | 3 | $49 |
| Amgen Inc. | 3 | $45 |
| Corium, LLC | 2 | $34 |
| Otsuka America Pharmaceutical, Inc. | 1 | $30 |
| Phathom Pharmaceuticals, Inc. | 1 | $25 |
| Lilly USA, LLC | 1 | $22 |
| Astellas Pharma US Inc | 1 | $21 |
Products named: Ozempic, TRELEGY ELLIPTA, Wegovy, ELIQUIS, OTEZLA, Azstarys, PREVNAR 20, REXULTI.
Industry payments across IN — which companies pay providers there.
